These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7648975)

  • 1. Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse.
    Louis E; Belaiche J; Van Kemseke C; Schaaf N; Mahieu P; Mary JY
    Dig Dis Sci; 1995 Aug; 40(8):1750-6. PubMed ID: 7648975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease.
    Louis E; Belaiche J; van Kemseke C; Franchimont D; de Groote D; Gueenen V; Mary JY
    Eur J Gastroenterol Hepatol; 1997 Oct; 9(10):939-44. PubMed ID: 9391781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease.
    Bross DA; Leichtner AM; Zurakowski D; Law T; Bousvaros A
    J Pediatr Gastroenterol Nutr; 1996 Aug; 23(2):164-71. PubMed ID: 8856584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells.
    Mueller C; Knoflach P; Zielinski CC
    Gastroenterology; 1990 Mar; 98(3):639-46. PubMed ID: 2298368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission.
    Van Kemseke C; Belaiche J; Louis E
    Int J Colorectal Dis; 2000 Aug; 15(4):206-10. PubMed ID: 11008719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune activation and nutritional status in adult Crohn's disease patients.
    Reimund JM; Arondel Y; Escalin G; Finck G; Baumann R; Duclos B
    Dig Liver Dis; 2005 Jun; 37(6):424-31. PubMed ID: 15893281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble interleukin-2 receptor and disease activity in Crohn's disease.
    Williams AJ; Symons JA; Watchet K; Duff GW
    J Autoimmun; 1992 Apr; 5(2):251-9. PubMed ID: 1627235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble interleukin-2 receptor as a marker of lymphocyte activation in childhood Crohn's disease.
    Proujansky R; Carpenter AB
    J Pediatr Gastroenterol Nutr; 1991 Oct; 13(3):277-84. PubMed ID: 1791504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases.
    Jung YS; Park JJ; Kim SW; Hong SP; Kim TI; Kim WH; Cheon JH
    Dig Liver Dis; 2012 Nov; 44(11):897-903. PubMed ID: 22721842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
    Niederau C; Backmerhoff F; Schumacher B; Niederau C
    Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut mucosal secretion of interleukin 1beta and interleukin-8 predicts relapse in clinically inactive Crohn's disease.
    Arnott ID; Drummond HE; Ghosh S
    Dig Dis Sci; 2001 Feb; 46(2):402-9. PubMed ID: 11281191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity.
    Crabtree JE; Juby LD; Heatley RV; Lobo AJ; Bullimore DW; Axon AT
    Gut; 1990 Sep; 31(9):1033-6. PubMed ID: 2210449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.
    Schreiber S; Howaldt S; Raedler A
    Gut; 1994 Aug; 35(8):1081-5. PubMed ID: 7926910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity.
    Nancey S; Hamzaoui N; Moussata D; Graber I; Bienvenu J; Flourie B
    Dig Dis Sci; 2008 Jan; 53(1):242-7. PubMed ID: 17549633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble interleukin-2 receptor, interleukin-6 and interleukin-1 beta in patients with Crohn's disease and ulcerative colitis: preoperative levels and postoperative changes of serum concentrations.
    Schürmann G; Betzler M; Post S; Herfarth C; Meuer S
    Digestion; 1992; 51(1):51-9. PubMed ID: 1639222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mononuclear cell activation in Crohn's disease. Evaluation using serum assay of neopterin and interleukin-2 soluble receptors].
    Duclos B; Reimund JM; Lang JM; Coumaros G; Chamouard P; Lehr L; Baumann R; Koehl C; Weill JP
    Gastroenterol Clin Biol; 1990; 14(1):22-7. PubMed ID: 2311849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease.
    Miranda-García P; Chaparro M; Gisbert JP
    Gastroenterol Hepatol; 2016 Oct; 39(8):508-15. PubMed ID: 27020243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis.
    Choy MY; Walker-Smith JA; Williams CB; MacDonald TT
    Gut; 1990 Dec; 31(12):1365-70. PubMed ID: 2101599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse.
    Yamamoto T; Umegae S; Kitagawa T; Matsumoto K
    Aliment Pharmacol Ther; 2004 Mar; 19(6):671-8. PubMed ID: 15023169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.